Biotech Movers: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

On April 17, 2014, Health authorities in England have approved an 18.7 million pound ($31 million) investment to provide Gilead Sciences, Inc. (NASDAQ:GILD), controversial new hepatitis C pill Sovaldi for seriously ill patients. Gilead Sciences, Inc. (NASDAQ:GILD), shares after opening at $69.37 moved to $70.64 on last trade day and at the end of the day closed at $70.00. Company price to sales ratio in past twelve months was calculated as 9.61 and price to cash ratio as 50.50. Gilead Sciences, Inc. (NASDAQ:GILD), showed a positive weekly performance of 6.90%.

On April 16, 2014, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares advanced 1.48% in last trading session and ended the day on $7.20. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), yearly performance is -60.26%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), saw unusually large options trading activity on Wednesday. Investors acquired 46,106 call options on the company, ARN reports. This is an increase of 822% compared to the average daily volume of 5,000 call options. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), shares moved down 1.90% in last trading session and was closed at $6.18, while trading in range of $ 6.16 – 6.33. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), year to date (YTD) performance is 5.64%.

MannKind Corporation (NASDAQ:MNKD), shares continued their decline on Monday following the news that a potential rival has filed for an IPO, says a report fromWallStreetPR. The news of the IPO along with the continued pullback from the news of the delay in approval of Afrezza dragged the shares down by 1.87% to $6.29. MannKind Corporation (NASDAQ:MNKD), weekly performance is -8.76%. On last trading day company shares ended up $6.25. MannKind Corporation (NASDAQ:MNKD), distance from 50-day simple moving average (SMA50) is 6.30%. Analysts mean target Price for the company is $7.57.